Subgroup analyses stratified by baseline mean age (≤60 or >60 years), BMI categories (overweight: BMI 25 ≤ BMI < 30; obesity: BMI ≥ 30), duration of GLP-1 RAs treatment (≤52 weeks, 52–104 weeks, or >104 weeks), treatment indication (type 2 diabetes or obesity), and type of comparator (placebo or other antidiabetic drugs) maybe reveal no significant association between GLP-1 RAs and the risk of esophageal cancer in any of these subgroups (Figure 3). This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.